Aptose Biosciences Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Stock-based Compensation (Tables)

Note 12 - Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2024

Notes To Financial Statements [Abstract]

Share-based Payment Arrangement, Option, Activity

Stock option transactions for the three months ended March 31, 2024 and March 31, 2023 are summarized as follows:


				Three months ended March 31, 2024
	Options (in thousands)			Weighted average exercise price		Weighted average remaining contractual life (years)
Outstanding, beginning of period		1,184		$	44.78		—
Granted		408			2.00		—
Exercised		—			—		—
Forfeited		(87	)		11.46		—
Outstanding, end of the period		1,505		$	34.98		7.04
Exercisable, end of the period		896		$	53.41		5.56
Vested and expected to vest, end of period		1,340		$	36.76		7.03


				Three months ended March 31, 2023
	Options (in thousands)			Weighted average exercise price		Weighted average remaining contractual life (years)
Outstanding, beginning of period		1,100		$	52.20		—
Granted		215			8.40		—
Exercised		—			0.00		—
Forfeited		(59	)		18.00		—
Outstanding, end of the period		1,256		$	46.65		7.01
Exercisable, end of the period		733		$	62.55		5.54
Vested and expected to vest, end of period		1,162		$	48.30		6.84

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

The following table presents the weighted average assumptions that were used in the Black‑Scholes option pricing model to determine the fair value of stock options granted during the period, and the resulting weighted-average fair values:


	Three months ended March 31, 2024			Three months ended March 31, 2023
Risk-free interest rate		4.07	%		3.41	%
Expected dividend yield		—			—
Expected volatility		83.1	%		80.3	%
Expected life of options (years)	5 years			5 years
Grant date fair value	$	1.36		$	6.60

Schedule of Share-based Payment Award, Options, Grants in Period

The following table presents the vesting terms of options granted in the period:


	Three months ended March 31, 2024		Three months ended March 31, 2023
	Number of options (in thousands)		Number of options (in thousands)
3-year vesting (50%-25%-25%)		20		48
4-year vesting (50%-16 2/3%-16 2/3%-16 2/3%)		388		167
Total stock options granted in the period		408		215

Share-based Payment Arrangement, Vesting and Redemption of the RSUs Granted


	Three months ended March 31, 2024				Three months ended March 31, 2023
	Number of options (in thousands)		Weighted average grant date fair value		Number of options (in thousands)			Weighted average grant date fair value
Outstanding, beginning of period		—	$	—		—		$	—
Granted		—		—		38			9.90
Vested and redeemed		—		—		(38	)		9.90
Outstanding, ending of period		—	$	—		—		$	—

Share-based Payment Arrangement, Expensed and Capitalized, Amount

The Company recorded share-based payment expense related to stock options and RSUs as follows:


	Three months ended March 31,
	2024		2023
Research and development	$	328	$	652
General and administrative		481		1,222
	$	809	$	1,874